Trials / Recruiting
RecruitingNCT06545630
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for R0 Resection of Colorectal Cancer Liver Metastases
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tumor antigen-sensitized DC vaccine | subcutaneous administration |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2025-11-01
- Completion
- 2026-05-01
- First posted
- 2024-08-09
- Last updated
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06545630. Inclusion in this directory is not an endorsement.